Clinical significance of the diagnosis of low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion.

BACKGROUND: The diagnosis of low-grade squamous intraepithelial lesion (LSIL), cannot exclude high-grade squamous intraepithelial lesion (LSIL-H) was not included in the 2001 Bethesda System. It is used in some institutions to diagnose cases that fulfill criteria for both the diagnosis of LSIL and atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H). In this study, the authors reviewed their experience with cases reported as LSIL-H during a 4-year interval. METHODS: Clinical information and histologic follow-up data were retrieved for Papanicolaou (Pap) tests (PTs) that were diagnosed as LSIL-H, LSIL, ASC-H and high-grade squamous intraepithelial lesion (HSIL) from January 1, 2004 to December 31, 2007. RESULTS: Of 235,645 PTs (97% SurePath) that were processed during the study period, the laboratory diagnosed 0.52% as ASC-H, 2% as LSIL, 0.30% as LSIL-H, and 0.39% as HSIL. Biopsy follow-up was available for 47%, 49%, 56.7% and 74% of these cases, respectively. Cervical intraepithelial neoplasia 2 (CIN-2) and CIN-3 or more severe lesions (CIN-3+) were identified on follow-up cervical biopsy more often in women who had diagnoses of LSIL-H and ASC-H (33.14% and 26.33%, respectively) than in women who had a diagnosis of LSIL (16.11%). CONCLUSIONS: The similarity of histologic follow-up results between LSIL-H and ASC-H suggested that the management of women who have a diagnosis of LSIL-H should be similar to the management of women who have a diagnosis of ASC-H.

Rate of endometrial adenocarcinoma in women screened before and after implementation of the Bethesda 2001 reporting system.

OBJECTIVE: To assess the impact of the recommendation of the 2001 Bethesda System to report all benign-appearing endometrial cells seen in women aged > or = 40 years on the frequency with which endometrial carcinomas are potentially detected as a consequence of Pap test reports that mention endometrial cells. STUDY DESIGN: We identified all women diagnosed with endometrial adenocarcinoma who also had a Pap test during the preceding 6 months. The search was performed for 3-year periods before and after the date of implementation of Bethesda 2001. RESULTS: Benign endometrial cells were reported for 589 women in the 3 years before Bethesda 2001 and for 3,810 women in the 3 following years. The number of endometrial malignancies found on follow-up in these women decreased from 8 in the 3 years before Bethesda 2001 to only 4 subsequently. The frequency of reporting atypical or malignant glandular cells, as well as the likelihood of finding endometrial malignancy on follow-up, did not significantly change. CONCLUSION: Despite a 6.5-fold rise in the frequency of reporting benign endometrial cells after Bethesda 2001, the frequency of subsequent diagnosis of endometrial malignancies did not in-crease.

Liquid-based Papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: study of 272 cases classified by the 2001 Bethesda system.

BACKGROUND: In addition to the reporting of atypical glandular cells (AGC) and adenocarcinoma (ADCA), the 2001 Bethesda System requires the reporting of benign-appearing endometrial cells in women aged >40 years (BAEMC). In this study, the authors evaluated the contribution of each of these reporting categories to the sensitivity and specificity of a liquid-based Papanicolaou test for endometrial carcinoma or hyperplasia. METHODS: Over the 3-year study period, in the setting of a large, multihospital health care system, the authors analyzed the results from liquid-based Papanicolaou tests that were performed within the 6 months that preceded a histologic diagnosis of endometrial carcinoma or hyperplasia and that were reported according to the 2001 Bethesda System. RESULTS: Two hundred seventy-two women had a histologic diagnosis of endometrial hyperplasia (n = 199) or malignancy (n = 73) within 6 months after a Papanicolaou test. In total, 188,594 Papanicolaou tests (91,385 from women aged >40 years) were interpreted during the study period and resulted in 3810 diagnoses of BAEMC, 326 diagnoses of AGC, and 30 diagnoses of ADCA. Only 28 of 73 women (38.4%) with endometrial carcinoma had cytologically AGC or ADCA reported on a previous Papanicolaou test. The reporting of BAEMC increased this sensitivity by only 5.5% (4 additional tests) but decreased the specificity of the Papanicolaou test for endometrial malignancy from 99.8% to 96%. For endometrial hyperplasias, the sensitivity of the Papanicolaou test was even lower (39 of 198 tests; 19.7%), but BAEMC represented the majority of endometrial-type cells reported (36 of 39 tests). CONCLUSIONS: The reporting of BAEMC led to an only marginal increase in sensitivity that had to be weighed against the significant loss in specificity of the Papanicolaou test for endometrial neoplasia.

Significance of benign endometrial cells in papanicolaou tests from women aged >or=40 years.

BACKGROUND: The 2001 Bethesda System recommends reporting benign endometrial cells (BECs) in women aged >or=40 years and considers these women at risk for endometrial pathology. The current study examines the relative risk of hyperplasia or malignancy conferred by the presence versus the absence of BECs in Papanicolaou (Pap) tests of women aged >or=40 years. METHODS: Women aged >or=40 years represented 29,177 (46.2%) of 63,202 Pap tests obtained over 1 year from a largely suburban screened population. Of these, 866 Pap tests (3%) showed BECs. Over the same 1 year period, 789 women aged >or=40 years had endometrial histologic evaluations between 14 days and 6 months following a Pap test. The Pap tests of 159 women had BECs, and 33 had atypical (n=32) or malignant (n=1) endometrial cells. The 597 remaining women, who had Pap tests without endometrial cells but who had endometrial sampling for other reasons, served as controls. RESULTS: There were nine endometrial hyperplasias (5.7%) and no adenocarcinomas in the BECs group, whereas 34 hyperplasias (5.7%) and 6 adenocarcinomas (1%) were diagnosed in the controls. These differences were not statistically significant, even after restricting the analysis to women aged >or=50 years or to women known to be postmenopausal. CONCLUSIONS: The current study found that women aged >or=40 years with BECs in their Pap tests did not have more endometrial hyperplasias or malignancies when compared with women who had endometrial sampling for reasons other than the presence of endometrial cells in a Pap test.

Interpretive yields of screening Pap tests and diagnostic Pap tests.

Recently, our laboratory has introduced the Medicare classification "diagnostic Papanicolaou (Pap) test" (DPT) for both conventional and liquid-based Pap tests. Because little is known regarding the diagnostic yield of DPT, we review our experience with these tests in a community with a low incidence of squamous intraepithelial lesions and contrast this with our experience with screening Pap tests (SPTs). A search of our laboratory's computerized data system identified all Pap tests classified as SPT and DPT from December 3, 2002 to December 2, 2003. The interpretations were tabulated and statistical comparisons were made. Between December 3, 2002 and December 2, 2003 63,626 Pap tests were interpreted (57,922 SPTs and 5704 DPTs). DPTs were far more likely to yield abnormal results (atypical squamous cells or worse, P<0.001) and were especially more likely to yield malignant results. These differences have numerous possible implications regarding screening, rescreening, and the design of studies that investigate the screening value of the Pap test.

Atypical cells in bronchoalveolar lavage specimens from bone marrow transplant recipients. A potential pitfall.

Numerous nonneoplastic conditions of the lungs may result in atypical cells in bronchoalveolar lavage (BAL) specimens mimicking malignant neoplasms. Bone marrow transplant (BMT) recipients have many predisposing factors that would lead to atypical cells in BAL specimens, presenting diagnostic challenges. We reviewed BAL specimens from BMT recipients and correlated our findings with clinical information. During a 5.5-year period, 21 BMT recipients had atypical cells in 27 BAL specimens at Fairview-University Medical Center, Minneapolis, MN. The atypical cells had the cytologic features of squamous or glandular cells. The nuclear/cytoplasmic ratio, atypical cells per case, and background varied from case to case. Most of the patients had 1 or more of the clinical findings that would lead to atypia in BAL specimens: 13 had recent cytoreductive treatment, 9 had positive cultures, and 7 had graft-vs-host disease. There was substantial overlap between the reactive atypia and carcinoma. Clinical correlation was the most important factor in making accurate diagnosis.

Pap test discrepancies and follow-up histology.

Papanicolaou (Pap) test discrepancy rates between cytotechnologists (CTs) and cytopathologists (CPs) are often kept to evaluate the performance of individual CTs. This is based on the unproven assumption that the CP's diagnoses are more likely to be correct. We investigated this assumption using data from our discrepancy files and comparing them to follow-up histology. All Pap test discrepancies were noted between January 1, 2001-December 31, 2001. Surgical pathology files were then searched for follow-up histology within 9 mo of the Pap test. Histologic diagnoses were compared with the previous CT and CP diagnoses, and then judged regarding accuracy. In total, 63,376 Pap tests were evaluated between January 1, 2001-December 31, 2001. There were 795 discrepancies throughout this period (1.25%). One hundred and sixty-six cases with discrepancies had follow-up histology within 9 mo of the Pap test (20.9%). Of downgraded cases (103), CPs were more correct in 51 cases (49.5%), whereas CTs were more correct in 52 cases (50.5%). Of upgraded cases (63), CPs were more correct in 19 cases (30.2%), whereas CTs were more correct in 44 cases (69.8%). Our results suggest that CPs are not more likely to be correct than CTs when there is a discrepancy with the diagnosis of a Pap test, especially when CPs upgrade CT diagnoses. This suggests that discrepancy data may be helpful for evaluating the performance of both CPs and CTs. It may also be of educational use for both CPs and CTs to know the follow-up histology in these cases.